HRTX vs PCRX
HRTX: Heron Therapeutics is a biotech company focused on commercializing extended-release postoperative pain and antiemetic therapies for acute care and oncology patients. PCRX: Pacira BioSciences is a specialty pharmaceutical company focused on developing non-opioid pain management solutions to improve the postsurgical patient experience.
Side-by-side fundamentals
| Metric | HRTX | PCRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $0.3582 | $36.39 | |
| Market cap | $68M | $1.5B | |
| P/E as of 2026-10-08 | n/a | 104.84 | |
| Net margin FY2025, SEC XBRL | n/a | +1.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +2.6% | |
| ROE FY2025, SEC XBRL | -140.9% | +1.0% | PCRX higher |
| ROA FY2025, SEC XBRL | -7.9% | +0.6% | PCRX higher |
| Debt / equity as of 2026-09-03 | 20.65 | 0.54 | PCRX lower |
| Revenue growth (YoY) as of 2026-09-03 | +1.0% | +5.7% | PCRX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.11 | 0.23 | |
| 1-year return as of 2026-10-08 close | -73.5% | +55.4% | PCRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.